TARS - Following Up On Tarsus Pharmaceuticals

2024-05-28 09:44:27 ET

Summary

• The stock of Tarsus Pharmaceuticals has doubled since it was first recommended in early September of last year.
• The initial rollout of XDEMVY has solidly exceeded expectations, and the company has also recently addressed its medium-term funding needs.
• An updated analysis of Tarsus Pharmaceuticals after the share's big recent gains follows in the paragraphs below.

Today, we put Tarsus Pharmaceuticals, Inc. ( TARS ) back in the spotlight. In early September, we concluded our initial piece on this pre-clinical biotech company, recommending the stock for a small ' starter ' position. The stock has moved up sharply since then. Given that, it seems a good time to circle back to Tarsus Pharmaceuticals. An updated analysis follows below....

For further details see: